Quick answer: latest quarter results, by ticker or company name

Reported Q: Q2 2025 Rev YoY: 0.0% EPS YoY: +108.3% Move: +5.00%

Cannabis Suisse Corp

CSUI

$0.00630 5.00%

Exchange OTC Sector Healthcare Industry Drug Manufacturers Specialty Generic

Q2 2025

Published: Jan 13, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for CSUI

Reported

Report Date

Jan 13, 2025

Quarter Q2 2025

Revenue

7.50K

YoY: 0.0%

EPS

0.00

YoY: +108.3%

Market Move

+5.00%

Previous quarter: Q1 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.01M up 0% year-over-year
Gross margin of 1.9%
Net income of 5.06K
"" -

CSUI

Company CSUI

Period Q2 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 9, 2026

Executive Summary

Cannabis Suisse Corp (CSUI) reported a flat revenue profile for QQ2 2025, with quarterly revenue of $7,500 and a minimal gross profit of $144 (gross margin 1.92%). The quarter’s profitability was dominated by a substantial GAAP operating expense load of $91,392, yielding an operating loss of $91,248 and an EBITDA of −$91,248 (EBITDA margin −12.17%). Net income of $5,062 appears to reflect a non-operating income item of $96,310, which temporarily conceals the deteriorating core earnings profile. On a cash-flow basis, operating cash flow was negative at $(19,142), and free cash flow was also $(19,142), with the cash balance ending at $4,100 versus $25,742 at the start of the period, underscoring a liquidity constraint.

Key Performance Indicators

Revenue

Stable

7.50K

QoQ: 0.00% | YoY: 0.00%

Gross Profit

Decreasing

144.00

1.92% margin

QoQ: 0.00% | YoY: -77.00%

Operating Income

Decreasing

-91.25K

QoQ: -21.93% | YoY: -79.97%

Net Income

Increasing

5.06K

QoQ: 100.95% | YoY: 109.24%

EPS

Increasing

0.00

QoQ: 101.32% | YoY: 108.33%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue and profitability: Revenue $7,500; YoY 0%, QoQ 0%; Gross profit $144; Gross margin 1.92%; EBITDA $(91,248); EBIT $(91,248); Operating loss margin −12.17%. Net income $5,062; Net margin 6.75%; EPS $0.0001. Cash flow: Operating cash flow $(19,142); Free cash flow $(19,142). Balance sheet health: Total assets $751,847; Total liabilities $2,627,701; Shareholders’ equity $(1,875,854) (negative). Liquidity: Current ratio 0.485; Quick ratio 0.485; Cash ratio 0.0147. Leverage and coverage: Total debt $236,669; Net debt $232,569; Retained earnings $(3,130,928). Valuation/market posture: Price-to-sales ~179.06x (extremely elevated given tiny revenue base); Price-to-book negative; Enterprise value multiple negative. Four-quarter trend suggests flat top-line but persistent non-cash/non-operational distortions in profitability.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	7.50K	0.00%	0.00%
Gross Profit	144.00	-77.00%	0.00%
Operating Income	-91.25K	-79.97%	-21.93%
Net Income	5.06K	109.24%	100.95%
EPS	0.00	108.33%	101.32%

Key Financial Ratios

Gross Profit Margin

Weak

1.92%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

-12.17%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Excellent

67.50%

Net profit margin is exceptional, indicating strong pricing power and operational efficiency

Return on Assets

Weak

0.67%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

0.00%

Return on equity suggests inefficient capital allocation

Current Ratio

Concern

0.49

Current ratio below safe levels, potential liquidity risk

Debt to Equity

Conservative

-0.13

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

High Growth

66.32x

Very high P/E indicates aggressive growth expectations, higher risk

Price to Book

Undervalued

-0.72x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2026	0.00	0.00	+0.0%	View
Q1 2026	0.00	0.00	+0.0%	View
Q3 2025	0.01	0.00	+0.0%	View
Q2 2025	0.01	0.00	+0.0%	View
Q1 2025	0.01	-0.01	+0.0%	View

CSUI

Cannabis Suisse Corp

Q2 2026 Report

Cannabis Suisse Corp (CSUI) QQ2 2026 Results Analysis – Near-Term Profitability Challenges, High Leverage, and Liquidity Pressure...

Read full report

CSUI

Cannabis Suisse Corp

Q1 2026 Report

Cannabis Suisse Corp (CSUI) QQ1 2026 Results – Operating losses persist despite non-operating income; Severe liquidity constraints and elevated leve...

Read full report

CSUI

Cannabis Suisse Corp

Q3 2025 Report

Cannabis Suisse Corp (CSUI) QQ3 2025 Earnings Analysis: Revenue Flat, Severe Leverage and Liquidity Strain Ambience...

Read full report

CSUI

Cannabis Suisse Corp

Q1 2025 Report

Cannabis Suisse Corp (CSUI) QQ1 2025 Results: Flat Revenue, Deep Losses and Elevated Leverage...

Read full report

Cannabis Suisse Corp (CSUI) Q2 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More CSUI Quarterly Reports

CSUI

CSUI

CSUI

CSUI

Q2 2025 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

CSUI Full Profile

CSUI Financial Statements

Earnings Calendar